211 related articles for article (PubMed ID: 21225912)
1. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
2. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
Renbarger JL; McCammack KC; Rouse CE; Hall SD
Pediatr Blood Cancer; 2008 Apr; 50(4):769-71. PubMed ID: 18085684
[TBL] [Abstract][Full Text] [Related]
3. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
[TBL] [Abstract][Full Text] [Related]
4. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
Skiles JL; Chiang C; Li CH; Martin S; Smith EL; Olbara G; Jones DR; Vik TA; Mostert S; Abbink F; Kaspers GJ; Li L; Njuguna F; Sajdyk TJ; Renbarger JL
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115708
[TBL] [Abstract][Full Text] [Related]
6. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
Sims RP
J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
[TBL] [Abstract][Full Text] [Related]
7. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
[TBL] [Abstract][Full Text] [Related]
8. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia.
Tay CG; Lee VWM; Ong LC; Goh KJ; Ariffin H; Fong CY
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28139029
[TBL] [Abstract][Full Text] [Related]
9. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
[TBL] [Abstract][Full Text] [Related]
10. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.
Lavoie Smith EM; Li L; Hutchinson RJ; Ho R; Burnette WB; Wells E; Bridges C; Renbarger J
Cancer Nurs; 2013; 36(5):E49-60. PubMed ID: 23842524
[TBL] [Abstract][Full Text] [Related]
11. Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.
Bosilkovska M; Ing Lorenzini K; Uppugunduri CR; Desmeules J; Daali Y; Escher M
Clin Ther; 2016 Jan; 38(1):216-20. PubMed ID: 26565076
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.
Dennison JB; Jones DR; Renbarger JL; Hall SD
J Pharmacol Exp Ther; 2007 May; 321(2):553-63. PubMed ID: 17272675
[TBL] [Abstract][Full Text] [Related]
13. Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.
Li Y; Kazuki Y; Drabison T; Kobayashi K; Fujita KI; Xu Y; Jin Y; Ahmed E; Li J; Eisenmann ED; Baker SD; Cavaletti G; Sparreboom A; Hu S
Drug Metab Dispos; 2024 Jan; 52(2):80-85. PubMed ID: 38071551
[TBL] [Abstract][Full Text] [Related]
14. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.
Lavoie Smith EM; Li L; Chiang C; Thomas K; Hutchinson RJ; Wells EM; Ho RH; Skiles J; Chakraborty A; Bridges CM; Renbarger J
J Peripher Nerv Syst; 2015 Mar; 20(1):37-46. PubMed ID: 25977177
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.
Shalaby N; Zaki HF; Badary OA; Kamal S; Nagy M; Makhlouf D; Elnashar A; Elnadi E; Abdelshafi SA; Abouelnaga S; Saber MM
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1391-1409. PubMed ID: 38680001
[TBL] [Abstract][Full Text] [Related]
16. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
[TBL] [Abstract][Full Text] [Related]
17. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies.
Dudeja S; Gupta S; Sharma S; Jain A; Sharma S; Jain P; Aneja S; Chandra J
Pediatr Hematol Oncol; 2019 Sep; 36(6):344-351. PubMed ID: 31514565
[TBL] [Abstract][Full Text] [Related]
18. Obesity as a Potential Risk Factor for Vincristine-induced Peripheral Neuropathy.
Sajdyk TJ; Boyle FA; Foran KS; Tong Y; Pandya P; Smith EML; Ho RH; Wells E; Renbarger JL
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e637-e640. PubMed ID: 31634238
[TBL] [Abstract][Full Text] [Related]
19. [A cohort study of vincristine-induced peripheral neuropathy in children].
Li C; Jin J; Huang J; Yang XY; Li Y; Yan YY; Yang C
Zhongguo Dang Dai Er Ke Za Zhi; 2023 May; 25(5):470-475. PubMed ID: 37272172
[TBL] [Abstract][Full Text] [Related]
20. Differential Interactions of Cytochrome P450 3A5 and 3A4 with Chemotherapeutic Agent-Vincristine: A Comparative Molecular Dynamics Study.
Saba N; Bhuyan R; Nandy SK; Seal A
Anticancer Agents Med Chem; 2015; 15(4):475-83. PubMed ID: 25634447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
